pyrroles has been researched along with bay 63-2521 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ghofrani, HA; Grimminger, F; Kalymbetov, A; Kojonazarov, B; Kretschmer, A; Lang, M; Schermuly, RT; Seeger, W; Stasch, JP; Tian, X; Weissmann, N | 1 |
| Ishida, H; Ishii, R; Katsuragi, S; Kogaki, S; Narita, J; Ozono, K; Suginobe, H; Tsuru, H; Ueyama, A; Wang, R; Yoshihara, C | 1 |
2 other study(ies) available for pyrroles and bay 63-2521
| Article | Year |
|---|---|
The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.
Topics: Animals; Apoptosis; Blood Pressure; Blotting, Western; Caspase 3; Cell Proliferation; Cyclic GMP; Guanylate Cyclase; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Immunohistochemistry; Indoles; Lung; Male; Nitric Oxide Synthase Type III; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Sildenafil Citrate; Soluble Guanylyl Cyclase; Sulfones; Time Factors; Treatment Outcome | 2012 |
Riociguat can ameliorate bronchopulmonary dysplasia in the SU5416 induced rat experimental model.
Topics: Animals; Animals, Newborn; Bronchopulmonary Dysplasia; Disease Models, Animal; Humans; Hyperoxia; Indoles; Infant, Newborn; Lung; Models, Theoretical; Pyrazoles; Pyrimidines; Pyrroles; Rats | 2021 |